Bispecific single chain Fv antibody molecules and methods of use therof
View Patent ↗Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
1. A method for treating a cancer that overexpresses HER2 and/or HER3 proteins, said method comprising administering to a patient in need thereof a therapeutically effective amount of a bispecific antibody molecule comprising a first scFv antibody that binds HER2/neu and a second scFv antibody that binds HER3, wherein the first scFv antibody binds an epitope of HER2/neu specifically bound by antibody C6-B1D2 and the second scFv antibody binds an epitope of HER3 specifically bound by antibody HER3.H3.
2. The method of claim 1 , wherein the cancer overexpresses HER2.
3. The method of claim 2 , wherein the cancer overexpresses HER2 and HER3.
4. The method of claim 1 , wherein the molecule is a single contiguous polypeptide.
5. The method of claim 4 , wherein the cancer overexpresses HER2.
6. The method of claim 5 , wherein the cancer overexpresses HER2 and HER3.
7. The method of claim 4 , wherein the first antibody is joined to the second antibody by a linker.
8. The method of claim 7 , wherein the cancer overexpresses HER2.
9. The method of claim 8 , wherein the cancer overexpresses HER2 and HER3.
10. The method of claim 7 , wherein the linker is a peptide linker.
11. The method of claim 10 wherein the cancer overexpresses HER2.
12. The method of claim 11 , wherein the cancer overexpresses HER2 and HER3.
13. The method of claim 1 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
14. The method of claim 2 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
15. The method of claim 4 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
16. The method of claim 5 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
17. The method of claim 7 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
18. The method of claim 8 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
19. The method of claim 10 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
20. The method of claim 11 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.
21. The method of claim 12 , wherein the specific binding to an epitope of HER2/neu is determined by ability to compete with the C6-B1D2 for binding to HER2/neu and specific binding to an epitope of HER3 is determined by ability to compete with HER3.H3 for binding to HER3.